Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CCKAR | P32238 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL623249 | 0.87 | GAA (0.47) | GAAHCRTR2HCRTR1KMT2AMEN1 | |
| SCHEMBL623910 | 0.76 | LMNA (0.42) | HCRTR2RAB9AACACBKDM4EALDH1A1 | |
| SCHEMBL624545 | 0.75 | RBP4 (0.49) | GAAKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL623899 | 0.75 | PTK2 (0.51) | KMT2AMEN1RAB9AACACBKDM4E | |
| SCHEMBL624639 | 0.74 | DRD2 (0.51) | GAAKMT2AMEN1RAB9AACACB | |
| SCHEMBL624165 | 0.73 | MEN1 (0.46) | GAAKMT2AMEN1RAB9AACACB | |
| SCHEMBL624189 | 0.73 | TP53 (0.44) | KMT2ARAB9AACACBKDM4EALDH1A1 | |
| SCHEMBL623245 | 0.73 | TSHR (0.53) | GAAKMT2AMEN1RAB9AKDM4E | |
| SCHEMBL623894 | 0.72 | RBP4 (0.51) | ACACB | |
| SCHEMBL623227 | 0.72 | HSD17B10 (0.45) | GAAKMT2AMEN1RAB9AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | claimed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | claimed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | claimed |
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | SCN5A, SCN2A, CACNA1G | GAA 1067/4885HCRTR2 651/4885HCRTR1 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.